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Secondary mtDNA Defects Do Not Cause Optic Nerve
Dysfunction in a Mouse Model of Dominant
Optic Atrophy
Patrick Yu-Wai-Man,1,2 Vanessa J. Davies,3,4 Malgorzata J. Piechota,4 Lynsey M. Cree,1
Marcela Votruba,4,5 and Patrick F. Chinnery1,6
PURPOSE. The majority of patients with autosomal dominant
optic atrophy (DOA) harbor pathogenic OPA1 mutations and
certain missense mutations, mostly within the GTPase domain,
have recently been shown to cause multiple mitochondrial
DNA (mtDNA) deletions in skeletal muscle. This raises the
possibility that the optic neuropathy could be the result of
secondary mtDNA defects accumulating within retinal gan-
glion cells (RGCs). To explore this hypothesis, the authors
looked for evidence of mitochondrial dysfunction in a mouse
model of DOA and documented the visual and neurologic
progression in aging mutant mice.
METHODS. Visual function was assessed with a rotating optoki-
netic (OKN) drum at ages 13 and 18 months and neurologic
phenotyping was performed using the primary SHIRPA screen
at age 13 months, comparing mutant Opa1/ mice with
wild-type C57Bl/6 mice. The presence of cytochrome c oxidase
(COX) deficiency and multiple mtDNA deletions was investi-
gated in gastrocnemius muscle and eye specimens harvested
from 2- and 11-month-old Opa1/ and Opa1/ mice.
RESULTS. At age 13 months, Opa1/ mice had a statistically
significant reduction in OKN responses compared to C57Bl/6
controls with both 2° and 8° gratings (P  0.001). At age 18
months, the difference between the two groups was significant
for the 8° grating (P  0.003) but not for the 2° grating (P 
0.082). Opa1/ mice did not exhibit any significant neuro-
muscular deficits and no COX deficient areas or secondary
mtDNA deletions were identified in skeletal muscle or the RGC
layer. There was also no evidence of significant mtDNA deple-
tion or proliferation in skeletal muscle from Opa1/ mice.
CONCLUSIONS. COX deficiency and mtDNA abnormalities do not
contribute to optic nerve dysfunction in pure DOA. (Invest
Ophthalmol Vis Sci. 2009;50:4561–4566) DOI:10.1167/iovs.09-
3634
Dominant optic atrophy (DOA; Online Mendelian Inheri-tance in Man [OMIM] 165500) is one of the most common
inherited optic neuropathies encountered in neuro-ophthalmo-
logical practice, and approximately 60% of affected individuals
will harbor a pathogenic mutation in the OPA1 gene (3q28-
q29).1,2 DOA was thought to have a relatively limited ocular
phenotype, with most patients experiencing an insidious onset
of central visual failure starting in early childhood due to the
focal loss of RGCs within the papillo-macular bundle.3 How-
ever, we and others have recently described DOA pedigrees
where the visual loss also segregated with more severe neuro-
muscular deficits such as progressive external ophthalmople-
gia (PEO), deafness, ataxia, myopathy, and peripheral neurop-
athy.4–6 Interestingly, skeletal muscle biopsies were available
from some of the affected family members, and these showed
unequivocal features of mitochondrial dysfunction with a mo-
saic pattern of COX-deficient muscle fibers and the presence of
multiple mtDNA deletions on long-range polymerase chain
reaction (PCR).4,5 The Opa1 protein is part of the large, dy-
namin GTPase family of mechanoenzymes and is located
within the inner mitochondrial membrane,7 providing intrigu-
ing causal links to the hitherto undescribed muscle changes in
these “DOA plus” pedigrees. The underlying pathophysiology
in DOA remains largely unexplained, and the accumulation of
secondary mtDNA abnormalities could represent an important
mechanism that triggers the downstream events leading to
cellular dysfunction and loss of function, especially within
RGCs. Basic research in DOA has been severely restricted by
the lack of affected human specimens and for this reason, we
have recently developed an Opa1 mouse model to explore
these fundamental molecular mechanisms in greater detail.8 To
determine the role of COX deficiency and secondary mtDNA
deletions in the RGC loss that characterizes DOA, we carried
out a physiological, biochemical, and molecular genetic study
in our mutant Opa1 mice.
MATERIALS AND METHODS
Opa1 Mice
We have established a mouse model of DOA (B6;C3-Opa1Q285STOP)
with a heterozygous nonsense mutation in exon 8 (c.1051CT) of the
Opa1 gene, which results in the introduction of a stop codon
(Q285STOP) and a 50% reduction in the expression of the Opa1
protein.8 Breeding, maintenance, and euthanatization were in compli-
ance with the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research. Homozygous mutant mice (Opa1/) died in
utero during embryogenesis but heterozygous Opa1/mice faithfully
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replicated the human phenotype, exhibiting a slowly progressive optic
neuropathy and demonstrating objective reduction in visual function
on psychophysical testing.
Visual Assessment
Visual function was formally assessed with a rotating optokinetic
(OKN) drum using high resolution 2° and low resolution 8° gratings,
which correspond to 0.25 and 0.0625 cycles/degree respectively, and
OKN responses were recorded using a validated protocol.9,10 We have
previously reported visual data on 6- and 12-month-old Opa1/ mice8
and in this study, further visual assessment was performed by one
investigator (VJD) on an older cohort of heterozygous mutant Opa1/
mice (n  14 at 13 months and n  12 at 18 months) and an age- and
sex-matched group of C57Bl/6 wild-type mice (n  14 at 13 months
and n  12 at 18 months). OKN data for both wild-type and mutant
mice was collected on the same day, under the same experimental
conditions.
Neurologic Evaluation
The primary SHIRPA examination is a comprehensive screening tech-
nique used to define abnormal mouse phenotypes in disease models.11
It consists of 37 separate general health and neurologic measures and
provides quantitative information on muscle, cerebellar, sensory, neu-
ropsychiatric, and autonomic functions (http://www.har.mrc.ac.uk/
services/phenotyping/neurology/shirpa.html). Using this assessment
tool, our heterozygous mutant Opa1/ mice did not show any gross
neuromuscular deficits at age 6 months and had a normal lifespan,
similar to their Opa1/ control littermates.8 In this study, 14 Opa1/
mice and 14 age- and sex-matched C57Bl/6 controls were reevaluated
at age 13 months with the primary SHIRPA protocol. This included
tests of muscle tone, power and coordination, as well as hearing using
the MRC standard click box (90 dB and 18–20 Hz).
Histochemistry
The gastrocnemius muscle was harvested from the leg area and both
eyes were enucleated from the following mice: 2-month-old Opa1/
(n  3), 2-month-old Opa1 (n  3), 11-month-old Opa1/ (n  3),
and 11-month-old Opa1/ (n  3). The muscle and eye specimens
were immediately frozen in a melting isopentane bath (–150°C) and
stored at –80°C. Serial sections were subsequently cut and mounted
onto glass slides using a cryostat (Microm HM560; Thermo Fisher,
Walldorf, Germany), at 20 m thickness for muscle and 12 m thick-
ness for the eye specimens. The tissue sections were then stained using
standard protocols for hematoxylin and eosin (H&E), cytochrome c
oxidase (COX), succinate dehydrogenase (SDH) and dual COX-
SDH.12,13 Myofibrillar adenosine triphosphatase (ATPase) staining,
with a pre-incubation pH of 4.3, was also performed on serial muscle
sections.14,15
DNA Extraction
Muscle homogenate DNA was extracted using a hard tissue kit (Nu-
cleon; Tepnel, Manchester, UK) but given the small quantities in-
volved, an alternative method was devised to obtain an adequate yield
of RGC DNA. Opa1 mouse eyes were serially sectioned onto mem-
brane slides and stained with dual COX-SDH to localize the RGC layer
and cell bodies (Fig. 1A). RGC blocks (100 m  500 m) were then
cut using a laser dissecting microscope (LMD 6000; Leica Microsys-
tems, Wetzlar, Germany) and collected into a 1.5 mL microcentrifuge
cap (Figs. 1B, 1C). A total of 200 RGC blocks were pooled together for
each mouse, with 10 RGC blocks dissected from 10 serial sections of
both right and left eyes. The dissection block included both the RGC
cell bodies and the proximal axonal segment within the retinal nerve
fiber layer. DNA extraction was performed using a purification kit
(QIAamp DNA Micro Kit; Qiagen, Crawley, UK) and eluted in 20 L of
TE buffer.
Long-range PCR Assay
Six primer pairs, available on request, were specifically designed to
amplify overlapping mtDNA regions and identify possible rearrange-
ments, especially in the mutational hotspots along the major arc of the
mitochondrial genome and involving MTND4 (Fig. 2A).16 A long-range
kit (Roche Expand Long-Range Kit; Roche Applied Science, Indianap-
olis, IN) was used with the manufacturer’s recommended cycling
procedures and the PCR products were electrophoresed in a 0.7%
agarose gel at 40 V for 3 hours.
Quantitative PCR Assay
Relative copy number was determined in homogenate muscle DNA
using a well-established iQ SYBR Green protocol on the real-time PCR
detection system (MyiQ; BioRad Laboratories, Hercules, CA), with
MTND5 as the mtDNA reference gene and GAPDH as the nuclear DNA
(nDNA) reference gene.17,18 Both assays were optimized and con-
firmed to be linear over an appropriate concentration range, and all
measurements were done in triplicate. The mtDNA/nDNA ratio was
derived from the difference in threshold cycle value (Ct) between
MTND5 and GAPDH, using the 2Ct method.
Statistical Analysis
Statistical analyses were performed using statistical software (SPSS v.
15; SPSS, Chicago, IL). An independent sample t-test and two-way
ANOVA were used to compare the OKN responses, primary SHIRPA
scores and mtDNA/nDNA ratio between mutant and wild-type mice, as
required. The error bars in the figures provided represent the standard
error of the mean (SEM).
FIGURE 1. Collection of RGCs from an 11-month-old Opa1/ mouse. (A) A 12 m cryostat section mounted onto a membrane slide. (B) Laser
microdissection of a 100 m  500 m block from the RGC layer. (C) RGC block in the microcentrifuge cap before cell lysis.
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RESULTS
Visual Function
Slit lamp and dilated fundal examinations did not reveal any
gross ocular pathology such as anterior segment dysgenesis,
cataracts, or retinal pigmentary changes in all Opa1 mice
studied. In this study, 13-month-old Opa1/ mice displayed
statistically significant decreased mean tracking frequency at
both 2° and 8° gratings (P  0.001) compared to wild-type
C57Bl/6 mice (main effect of genotype, P  0.001; main effect
of grating, P  0.435; grating by genotype interaction, P 
0.461; Fig. 3A). At age 18 months, the difference between
mutant and control groups was significant for the 8° grating
(P  0.003) but not for the 2° grating (P  0.082; Fig. 3B).
There was also a statistically significant reduction in OKN
responses between the 2° and 8° gratings at age 18 months
(main effect of genotype, P 0.325; main effect of grating, P
0.001; grating by genotype interaction, P 0.880). The ratio of
mean tracking frequency (C57Bl/6 vs. Opa1/) was 1.53 for
the 2° grating and 1.70 for the 8° grating at age 13 months, and
1.05 for the 2° grating and 1.06 for the 8° grating at age 18
months.
Neurologic Phenotype
The primary SHIRPA neurologic examination did not reveal any
functional neurologic deficits in the Opa1/ mice at age 13
months. No gait abnormalities or tremor were present at rest-
ing level and there was no statistically significant difference in
limb tone, grip strength, and muscle coordination between
mutant and wild-type mice. Compared to wild-type C57Bl/6
controls, Opa1/ mice had increased transfer arousal and
locomotor activity scores, indicating that they were possibly
more anxious and fearful in novel environments (P 0.05). All
the Opa1/ mice tested had normal hearing test results with
the MRC standard click box.
Histology and mtDNA Analysis
In the 12 Opa1 mice that were studied, H&E and myofibrillar
ATPase staining showed normal muscle fiber morphology,
with no inflammatory or neuropathic changes such as muscle
fiber necrosis, regeneration, or fiber type grouping. There
were no ragged red fibers (RRFs) on SDH staining and no COX
deficient fibers were identified, with an average sampling of
3793 muscle fibers for each mouse (SD, 1049; range, 1690–
5302; Fig. 4). Similarly, we found no evidence of COX-deficient
regions within the RGC layer of both the 2-month and 11-
month-old Opa1/ and Opa1/ mice (Fig. 5). The long-
range PCR assay using all 6 primer pairs only amplified full
mtDNA fragments with no evidence of smaller amplicons in
both control and mutant groups (Fig. 2B). There was no statis-
tically significant difference in mtDNA/nNDA ratio in muscle
from Opa1/ (mean, 16.58; SD, 2.71; n  6) and Opa1/
mice (mean, 15.17; SD, 4.51; n  6; P  0.795; Fig. 6).
FIGURE 2. (A) Location of the mtDNA products amplified with our long-range PCR primer pairs: I (2,773–10,833; 8,060 bp), II (11,172–14,446;
3,274 bp), III (8,309–14,993; 6,684 bp), IV (8,381–14,446; 6,065 bp), V (3,106–10,595; 7,489 bp), and VI (13,053–15,053–2,000 bp). (B) Agarose
gel (0.7%) showing the products generated with primer pairs IV, V, and VI, respectively. (a–c) RGC DNA extracted from our three 11-month-old
Opa1/ mice; (d) RGC DNA extracted from one 11-month-old Opa1/ mouse; (e) muscle homogenate DNA extracted from the same
11-month-old Opa1/ mouse; and 1 Kb DNA ladder with 1, 2, 3, 6, and 10 Kb bands indicated).
FIGURE 3. Performance on the optokinetic visual screening test ex-
pressed as the mean frequency of tracking a moving 2° and 8° grating
for 2 minutes at (A) 13 months: Opa1/ mice (n  14) and C57Bl/6
controls (n  14); (B) 18 months: Opa1/ mice (n  12) and C57B6
controls (n  12). **P  0.001; *P  0.003; NS, non-significant at P 
0.082.
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DISCUSSION
We previously reported a significant reduction in OKN re-
sponses in our heterozygous mutant Opa1/ mice age 12
months compared to their littermate controls. In this report,
we extended our observations to a more aged colony and
further confirm that the pathogenic variant in exon 8
(c.1051CT) of the Opa1 gene leads to optic nerve dysfunc-
tion in our heterozygous mutant mice. The optic neuropathy is
relatively mild, as none of the Opa1/ mice completely failed
to track the gratings, consistent with the better visual progno-
sis in DOA compared to other inherited optic neuropathies
such as Leber hereditary optic neuropathy (LHON; OMIM
535000).3 There was a statistically significant reduction in
FIGURE 4. Serial 20-m-thick limb
muscle sections from an 11-month-
old Opa1/ mouse stained with (A)
H&E, (B) COX, (C) SDH, and (D)
COX-SDH. The darker-staining mus-
cle fibers are type I and reflect their
higher mitochondrial oxidative ca-
pacity. A similar fiber type distribu-
tion was observed in all Opa1 mice
studied, irrespective of age or muta-
tional status.
FIGURE 5. Serial 12-m-thick eye
sections from an 11-month-old
Opa1/ mouse stained with (A)
H&E, (B) COX, (C) SDH, and (D)
COX-SDH. Co, cornea; L, lens; On,
optic nerve; R, retina.
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mean tracking frequency between Opa1/ mice and C57Bl/6
controls for both 2° and 8° gratings at age 13 months, but the
difference was only significant for the 8° grating at age 18
months. The most likely explanation is a loss of visual acuity
occurring with age for the C57Bl/6 mice, which reduced the
difference between mutant and wild-type mice at the higher
resolution 2° grating but not at the lower resolution 8° grating.
The OKN ratios at age 13 and age 18 months also suggest that
visual acuity does not deteriorate further with advancing age in
our Opa1/ mice, which is similar to the natural history of
DOA in humans, where less than 50% of affected patients
experience further, albeit gradual, deterioration in their visual
function on long-term follow-up.19–21
A comprehensive histochemical analysis of muscle and eye
specimens failed to demonstrate any COX deficient areas and
no mtDNA deletions were identified using our long-range PCR
assay. Quantitative analysis on homogenate muscle DNA also
showed no evidence of significant mitochondrial depletion or
proliferation in the Opa1/ mice compared to Opa1/
controls. If the pathogenic Opa1 mutation induced these sec-
ondary mitochondrial changes, we would have expected these
to be apparent in the 11-month-old Opa1 mice, an age group
in which visual dysfunction had already developed. In addition,
we previously showed with electron microscopy that signifi-
cant morphologic changes were clearly visible by the age of 9
months within the optic nerve, with abnormally swollen and
distorted RGC axons, and irregular areas of demyelination and
myelin aggregates along the nerve fiber bundles.8,22 A limita-
tion of our experimental procedures is the inability to visualize
individual RGC cell bodies and axons due to their small size,
and it is possible that isolated COX deficient RGCs were
present that have been missed. However, long-range PCR is a
very sensitive molecular technique because of its preferential
amplification of smaller mtDNA species and yet, enriching for
RGCs by laser microdissection did not reveal any mtDNA de-
letions.23 Another possible argument is that COX deficient
RGCs were present in the pre-clinical stages but these were
then lost coincident with the onset of optic nerve dysfunction.
Although we cannot absolutely exclude this scenario, it is
somewhat unlikely given the consistent observations of viable
COX-deficient neurons in brain biopsies from patients with
neurodegenerative disorders such as Parkinson’s disease,
where COX-deficient neurons accumulate both with increasing
age and progression of the disease process.24,25 Furthermore,
previous retinal histologic analysis of our Opa1/ mice did
not show any significant reduction in total RGC count.8
How can we then account for this apparent disparity be-
tween our Opa1 mouse model and the recent reports of COX
deficiency and multiple mtDNA deletions in “DOA plus” ped-
igrees? We recently investigated a cohort of 21 patients with
multi-systemic neuromuscular disorders, COX-deficient muscle
fibers, and multiple mtDNA deletions.26 Initial mutational
screen for genes previously described in patients with multiple
mtDNA deletions was negative: POLG1, POLG2, SLC25A4, and
PEO1, but subsequent OPA1 gene sequencing identified patho-
genic variants in three probands who also had visual failure;
that is, 14% of our study cohort. Although the underlying
mechanisms are unknown, this very interesting finding pro-
vides additional robust evidence that some OPA1 mutations do
lead to the formation and clonal expansion of mtDNA dele-
tions.
All the causative OPA1 mutations in these “DOA plus”
families have so far been missense mutations with most, but
not all of them, within the catalytic GTPase site of the pro-
tein.4–6 Although functional studies are lacking, it has been
speculated that the more severe phenotype is the consequence
of the mutant Opa1 protein exerting a dominant negative
effect, and the more severe cellular dysfunction becomes ap-
parent not only within RGCs, but also in other “at-risk mito-
chondrial” tissues such as extra-ocular muscles, skeletal mus-
cle, and brain.27 If this hypothesis is substantiated, it is perhaps
not surprising that we failed to detect these abnormalities in
our Opa1 mutant mice, where the pathology is limited to the
optic nerve, that is, “pure DOA,” with no evidence to suggest
additional neurologic deficits such as muscle weakness, ataxia,
or deafness, using the well-validated primary SHIRPA screen.11
The heterozygous exon 8 mutation (c.1051CT) in our Opa1
mice is also truncative (Q285STOP) and overall results in a 50%
reduction in the expression of the Opa1 protein, thereby
representing a haploinsufficiency, and not a dominant nega-
tive, disease model. We previously showed the following per-
centage decrease in Opa1 protein levels in a panel of post-
mitotic tissues harvested from Opa1/ mice: retina (55%),
brain (50%), skeletal muscle (80%), heart (55%), liver (80%),
kidney (35%), and spleen (65%).8
Although our results relate only to this specific mouse
model, one could speculate that secondary mtDNA abnormal-
ities do not contribute to optic nerve dysfunction among pa-
tients with truncative OPA1 mutations and a “pure DOA”
phenotype. It is perhaps also premature to conclude that COX
deficiency and multiple mtDNA deletions are a sine qua non for
a more severe disease progression in DOA. Spinazzi and col-
leagues28 have recently described a large, multi-generational
pedigree where the optic atrophy segregated with mild myop-
athy and an axonal sensory-motor peripheral neuropathy. In
contrast to previous “DOA plus” pedigrees, COX deficient
muscle fibers and multiple mtDNA deletions were absent and a
novel OPA1 deletion in the GTPase domain (c.1410_
14434del38) was identified that reduced the level of protein
expression by half; that is, led to haploinsufficiency. Functional
studies performed on fibroblast and myoblast cultures showed
no demonstrable respiratory chain defects, in contrast to the
common c.2708_2711delTTAG OPA1 deletion, which has
been shown to inhibit mitochondrial oxidative phosphoryla-
tion in both in vitro fibroblast29 and in vivo muscle assays.30
However, the c.1410_14434del38 mutation led to marked
fragmentation of the mitochondrial network, an effect also
seen with other OPA1 mutations3 and in fibroblasts derived
from our mouse model,8 highlighting the additional important
pro-fusion function of the Opa1 protein.
Opa1 is proving to be a multi-faceted protein with several
crucial molecular roles relating to mtDNA replication, oxida-
tive phosphorylation, maintenance of the mitochondrial net-
work and apoptosis. The challenge ahead will be to unravel
how OPA1 mutations actually lead to loss of function, not only
in RGCs, but also in other post-mitotic tissues to explain the
expanding clinical spectrum being documented in DOA fami-
lies. In this respect another Opa1 mouse model with more
FIGURE 6. Comparison of mitochondrial copy number in homogenate
muscle DNA extracted from OPA1/ and OPA1/ mice. NS, not
significant at P  0.795.
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severe neurologic deficits in addition to the optic neuropathy
would provide invaluable insights into these molecular mech-
anisms and how they interact to cause disease. Understanding
these key pathophysiological steps will hopefully lead to the
development of effective neuroprotective strategies with clin-
ical benefits to patients with DOA.
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